Report
Valens Research

CME - Embedded Expectations Analysis - 2020 10 06

CME Group Inc. (CME:USA) currently trades above corporate averages relative to UAFRS-based (Uniform) earnings, with a 34.3x Uniform P/E. At these levels, markets have bullish expectations for the firm, but management may have concerns about expenses, returns, and their client base

Specifically, management may be overstating their responsiveness to the crisis, their expense discipline, and the potential of the Ultra Bond futures. In addition, they may lack confidence in their ability to capitalize on their next acquisition, maintain revenues, and generate investor interest for their upcoming benchmarks. Furthermore, they may have concerns about the sustainability of demand in display devices, continued declines in the product mix with their active trader segment, and perpetual reduction in their net returns, particularly from their joint venture with S&P. Additionally, they may lack confidence in their ability to sustain their realized synergies, enhance their oil and gas contract with commercial customers, and expand their client base. Moreover, they may be concerned about the price of their micro products from a risk-adjusted perspective, and the additional volumes and volatility from the Federal Reserve's actions
Underlying
CME Group Inc. Class A

CME Group is a holding company. Through its subsidiaries, the company exchanges provides a range of global benchmark products across asset classes based on interest rates, equity indexes, foreign exchange (FX), agricultural, energy and metal commodities. The company provides futures and options on futures trading across asset classes through its subsidiary, Chicago Mercantile Exchange Inc. (CME) Globex platform, cash and repo fixed income trading via BrokerTec, and cash and OTC FX trading via EBS. In addition, the company operates central counterparty clearing providers, CME Clearing, a division of CME. The company also provides optimization, reconciliation and processing services through TriOptima, Traiana and Reset.

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch